Depomed Initiates Phase I Trial For DM-1992 Program In Parkinson’s Disease Following Positive Results Of Preclinical Studies

Depomed, Inc. (NASDAQ:DEPO) announced that it has dosed the first patient in a Phase I trial for its DM-1992 program in Parkinson’s disease based on positive results from preclinical studies sponsored by The Michael J. Fox Foundation for Parkinson’s Research. DM-1992 is an investigative novel gastric retentive extended-release dosage form of Levodopa/Carbidopa, a marketed therapy used in the treatment of Parkinson’s disease.

More: continued here

Filed under: Parkinson's Disease on February 20th, 2009